Characterizing the preserved ratio impaired spirometry phenotype in all severities of asthma
The PRISm asthma phenotype is associated with greater exacerbation frequency, poorer symptom control and a higher SAD prevalence compared to patients with normal spirometry. Future research should focus on longitudinal follow-up to confirm the progression of PRISm to obstructive patterns and assess potential therapeutic interventions to modify this trajectory.
Authors
- Stanley P. Galant (ORCID: https://orcid.org/0000-0002-8151-7647)
- Rory Chan (ORCID: https://orcid.org/0000-0003-2805-8266)
- Carlo Mario Lombardi (ORCID: https://orcid.org/0000-0002-7120-5877)
- Alvise Berti (ORCID: https://orcid.org/0000-0002-7831-921X)
- Atanu Bhattacharjee (ORCID: https://orcid.org/0000-0002-5757-5513)
- Pasquale Comberiati (ORCID: https://orcid.org/0000-0001-5209-9733)
- Remo Poto (ORCID: https://orcid.org/0000-0002-4723-0167)
- Marcello Cottini (ORCID: https://orcid.org/0000-0003-2767-6767)
- Brian J. Lipworth (ORCID: https://orcid.org/0000-0002-8140-2014)
- Erol Gaillard (ORCID: https://orcid.org/0000-0003-0996-8133)
- Francesco Menzella (ORCID: https://orcid.org/0000-0003-3950-5789)
- Robert Greig (ORCID: https://orcid.org/0000-0001-7668-286X)
- Laura Ventura (ORCID: https://orcid.org/0000-0001-7322-998X)
Institutions
- University of Pisa (IT)
- Children's Hospital of Orange County (US)
- University of Padua (IT)
- University of Dundee (GB)
- University of Trento (IT)
- Ospedale Santa Chiara (IT)
- AULSS 2 Marca Trevigiana (IT)
- Provincia Autonoma di Trento (IT)
- Federico II University Hospital (IT)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- NIHR Leicester Biomedical Research Centre (GB)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Respiratory Medicine
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1016/j.rmed.2025.108180
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals
- Glenmark Pharmaceuticals